Search Result

Results for "

CPDs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (2) Btk (1) CDK (3) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (3) Endogenous Metabolite (1) Epigenetic Reader Domain (2) Ferroptosis (1) FGFR (1) Histone Acetyltransferase (1) Indoleamine 2,3-Dioxygenase (IDO) (1) IRE1 (1) JAK (2) Ligands for Target Protein for PROTAC (2) PARP (2) PD-1/PD-L1 (1) Potassium Channel (1) PROTAC Linkers (2) PROTACs (4) Sex Pheromone (1) Small Interfering RNA (siRNA) (3) STAT (1) TAM Receptor (1) Toll-like Receptor (TLR) (1) Trk Receptor (1) VEGFR (1)
By Research Areas:	Cancer (24) Cardiovascular Disease (2) Endocrinology (1) Infection (2) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (3)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-143498

ERCC1-XPF-IN-1	DNA/RNA Synthesis	Cancer
ERCC1-XPF-IN-1 is a potent and high-affinity ERCC1-XPF inhibitor with IC₅₀ value of 0.49 μM. ERCC1-XPF-IN-1 has the capacity to potentiate the cytotoxicity effect of UV radiation and inhibiting DAN repair, by the inhibition of removal of CPDs, and cyclophosphamide toxicity to colorectal cancer cells .

HY-168660

CPD-10 1 Publications Verification	PROTACs Apoptosis CDK	Cancer
CPD-10 is a potent CCND1 and CDK4 PROTAC degrader. CPD-10 shows anti-proliferation. CPD-10 induces apoptosis. CPD-10 decreases the protein expression of cyclin D1, cyclin D3, CDK4, P-Rb(5807/811) in a dose-dependent manner. (Pink: ligand for target protein (HY-50767); black: linker (HY-22391); Blue: E3 ligase ligand (HY-168667)) .

HY-153386

CPD-1224	Anaplastic lymphoma kinase (ALK)	Cancer
CPD-1224 is an orally effective ALK inhibitor, a derivative of an ALK inhibitor that connects to the cereblon ligand. CPD-1224 targets the EML4-ALK oncogenic fusion protein and degrades both ALK and the mutant forms L1196M/G1202R. CPD-1224 can slow down tumor growth .

HY-168664

CPD-39	PROTACs CDK	Cancer
CPD-39 is a potent and orally active CCND1 and CDK4 heterobifunctional PROTAC degrader. CPD-39 shows anti-proliferation. (Pink: ligand for target protein (HY-50767); black: linker (HY-20240); Blue: E3 ligase ligand (HY-168667)) .

HY-147310

*CU-CPD107*	Toll-like Receptor (TLR)	Infection
CU-CPD107 is a potent, selective toll-like receptor 8 (TLR 8) agonist. CU-CPD107 inhibits TLR8 signaling. CU-CPD107 converts to synergistic agonist activities in the presence of ssRNA and induces TLR8 signaling. CU-CPD107 inhibits proinflammatory factor expression and avoids immune responses in the presence of ssRNA .

HY-174991

CPD-2828	IRE1	Neurological Disease Cancer
CPD-2828 is an orally active and selective IRE1α inhibitor with an IC₅₀ value of 1.2 μM. CPD-2828 is promising for research of endoplasmic reticulum stress-related diseases (e.g., cancer, neurodegenerative diseases) .

HY-168662

Palbociclib-CH2COOH	Ligands for Target Protein for PROTAC	Cancer
Palbociclib-CH2COOH is a Ligands for Target Protein for PROTACs. Palbociclib-CH2COOH can serve as an active control for the target protein ligand of CPD-39 (HY-168664) and CPD-10 (HY-168660) .

HY-144028

Pan-Trk-IN-2	Trk Receptor	Cancer
Compound cpd-1 is a small molecule Trks inhibitor with good antitumor activity .

HY-163533

CPD-002	VEGFR	Inflammation/Immunology
CPD-002 is an inhibitor for vascular endothelial growth factor receptor 2 (VEGFR 2), that inhibits angiogenesis through inhibition of VEGFR2/PI3K/AKT signaling pathway. CPD-002 exhibits anti-inflammatory activity and attenuates rheumatoid arthritis .

HY-158340

TYK2 ligand 1	JAK Ligands for Target Protein for PROTAC	Cancer
TYK2 ligand 1 is a TYK2 ligand in the synthesis of PROTAC-based TYK2 degrader (CPD-155, HY-158142) .

HY-RS18891

Cpd Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cpd Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cpd gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cpd Mouse Pre-designed siRNA Set A Cpd Mouse Pre-designed siRNA Set A

HY-RS03089

CPD Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CPD Human Pre-designed siRNA Set A contains three designed siRNAs for CPD gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CPD Human Pre-designed siRNA Set A CPD Human Pre-designed siRNA Set A

HY-RS25382

Cpd Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cpd Rat Pre-designed siRNA Set A contains three designed siRNAs for Cpd gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cpd Rat Pre-designed siRNA Set A Cpd Rat Pre-designed siRNA Set A

HY-168667

E3 ligase Ligand 40	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 ligase Ligand 40 is a conjugate of E3 ligase ligand and linker that serve as a key intermediate for the synthesis of complete PROTAC molecule CPD-39 (HY-168664) .

HY-168668

E3 Ligase Ligand-linker Conjugate 132	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 132 is a conjugate of E3 ligase ligand and linker that serve as a key intermediate for the synthesis of complete PROTAC molecule CPD-39 (HY-168664) .

HY-168663

E3 Ligase Ligand-linker Conjugate 131	E3 Ligase Ligand-Linker Conjugates	Cancer
E3 Ligase Ligand-linker Conjugate 131 is a conjugate of E3 ligase ligand and linker that serve as a key intermediate for the synthesis of complete PROTAC molecule CPD-10 HY-168660 .

HY-20240

tert-Butyl (6-aminospiro[3.3]heptan-2-yl)carbamate	PROTAC Linkers	Cancer
tert-Butyl (6-aminospiro[3.3]heptan-2-yl)carbamate is a linker that can be used for synthesis of PROTAC degrader CPD-39 (HY-168664) .

HY-22391

tert-Butyl (7-aminoheptyl)carbamate tert-Butyl 2,8-diaminooctanoate	PROTAC Linkers	Cancer
tert-Butyl (7-aminoheptyl)carbamate (tert-Butyl 2,8-diaminooctanoate) is a PROTAC linker. tert-Butyl (7-aminoheptyl)carbamate can be used to synthesis CPD-10 (HY-168660) .

HY-170322

TDO2-IN-1	Indoleamine 2,3-Dioxygenase (IDO)	Metabolic Disease
TDO2-IN-1 (Cpd-2) is a potent inhibitor of Human TDO2, with the IC₅₀ of 14.8 nM. TDO2-IN-1 plays an important role in metabolism, inflammation, and tumor immune surveillance research .

HY-161606

PARP-1/2/7-IN-1	PARP	Cancer
PARP-1/2/7-IN-1 (compound 86) is a potent inhibitor of PARP-1/2/7, with the IC₅₀ of ＜ 10 nM .

HY-161607

PARP7-IN-21	PARP	Cancer
PARP7-IN-21 (compound 128) is a potent inhibitor of PARP7, with the IC₅₀ of ＜ 10 nM .

HY-N7893

*Ebracteolata cpd* B**	Others	Others
Ebracteolata cpd B is a natural phenol compound found in Euphorbia ebracteolata .

HY-158142

PROTAC TYK2 degrader-1	PROTACs JAK	Cancer
PROTAC TYK2 degrader-1 (CPD-155) is a PROTAC targeting degrader to TYK2 with D_max >60%. (Structure Note: PINK, TYK2 ligand 1 (HY-158340); Blue, VHL ligand Thalidomide (HY-14658); Black, linker)

HY-134621

P300-IN-1	Histone Acetyltransferase	Cancer
P300-IN-1 (cpd205) is a Histone acetylase p300 inhibitor .

HY-160167

Birelentinib	Btk	Inflammation/Immunology
Birelentinib (compound cpd15) is an inhibitor of Bruton's tyrosine kinase (BTK) and mutant BTK with IC₅₀ values of 6.72 and 6.11 nM, respectively .

HY-153441

AXL-IN-15	TAM Receptor	Cancer
AXL-IN-15 (cpd391) is a potent Axl inhibitor with both K_i and IC₅₀ <1 nM. AXL-IN-15 can be used for research in cancer .

HY-P4914

Sex Pheromone Inhibitor iPD1	Sex Pheromone	Others
Sex Pheromone Inhibitor iPD1 is a sex pheromone inhibitor. Sex Pheromone Inhibitor iPD1 inhibits the sex pheromone cPD1 .

HY-P4523

FA-Ala-Arg	Endogenous Metabolite	Endocrinology
FA-Ala-Arg is a dipeptide with furylacryloyl group. FA-Ala-Arg breaks down to produce arginine. While cell-surface Carboxypeptidase-D (CPD) also increases intracellular Arg, which is converted to nitric oxide (NO). FA-Ala-Arg enhances NO production in MCF-7 cells. FA-Ala-Arg also increases the cell survival of prolactin (PRL)-treated cells, PRL regulates CPD mRNA levels in cells .

HY-174416

Smurf1-IN-5	E1/E2/E3 Enzyme	Cardiovascular Disease
Smurf1-IN-5 (Compound cpd-6) is an allosteric SMAD ubiquitin regulatory factor 1 (SMURF1) inhibitor. Smurf1-IN-5 leads to a reduction in the ubiquitylation of substrates such as BMPR2 (bone morphogenetic protein receptor 2) and SMAD1, enhancing the BMP (bone morphogenetic protein) signaling pathway. Smurf1-IN-5 is promising for research of pulmonary arterial hypertension (PAH) .

HY-163705

*BR-cpd7*	PROTACs FGFR	Cancer
BR-cpd7 is a PROTAC degrader for fibroblast growth factor receptor FGFR1/2 with DC₅₀ of 10 nM. BR-cpd7 arrests cell cycle, inhibits proliferations of FGFR1/2 aberrant activated tumor cells. (Pink: ligand for target protein FGFR-IN-12 (HY-160013); Black: linker; Blue: ligand for E3 ligase Thalidomide-NH-CH2-COOH (HY-131717))

HY-158009

SGF29-IN-1	Others	Cancer
SGF29-IN-1 (Compound Cpd_DC60) is a selective inhibitor for Spt-Ada-Gcn5 acetyltransferase (SAGA)–associated factor 29 (SGF29)-Tudor domain. SGF29-IN-1 exhibits activity against leukemia .

HY-W471937

α1B-AR antagonist 1	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
α1b-AR antagonist 1 (Compound Cpd1) is a selective α₁B-AR antagonist. Alpha1b-ar antagonist 1 can be used in the study of cardiovascular and central nervous system diseases .

HY-178488

BRM/BRG1 ATP-IN-7	Epigenetic Reader Domain	Infection Cancer
BRM/BRG1 ATP-IN-7 (Compound Cpd69) is a selective dual BRM (SMARCA2) and BRG1 (SMARCA4) inhibitor with IC₅₀ values of 12 nM and 8 nM, respectively. BRM/BRG1 ATP-IN-7 is promising for research of BRM/BRG1-dependent cancers (e.g., non-small cell lung cancer, Ewing sarcoma) and virus-associated diseases (e.g., HPV infection) .

HY-172455

TREK inhibitor-3	Potassium Channel	Neurological Disease
TREK inhibitor-3 (Cpd8l) is a selective and BBB-permeable TREK-1 inhibitor with an IC₅₀ of 0.81 μM. TREK inhibitor-3 has neuroprotective effects, which can significantly reduce the death of cortical neurons induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and improve brain injury in mice models of middle cerebral artery occlusion/reperfusion (MCAO/R). TREK inhibitor-3 can be used in the research of ischemic stroke .

HY-178490

BRM/BRG1 ATP-IN-8	Epigenetic Reader Domain	Cancer
BRM/BRG1 ATP-IN-8 (Compound Cpd14) is an orally active BRG1/BRM ATPase domain inhibitor. BRM/BRG1 ATP-IN-8 exerts antitumor effects by disrupting aberrant chromatin remodeling in cancer cells, inducing apoptosis and growth arrest. BRM/BRG1 ATP-IN-8 is promising for research of BRG1/BRM-dependent malignancies, including hematological cancers, prostate cancer, breast cancer, and Ewing's sarcoma .

HY-171786

CDK12-IN-8	CDK	Cancer
CDK12-IN-8 (Compound Cpd143) is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). CDK12-IN-8 inhibits CDK12-mediated phosphorylation of the C-terminal domain (CTD) serine 2 of RNA polymerase II, interfering with gene transcription elongation and DNA damage repair pathways. CDK12-IN-8 is promising for research of cancers with high CDK12 expression such as small cell lung cancer and triple-negative breast cancer .

HY-169059

Ferroptosis-IN-12	Ferroptosis	Inflammation/Immunology
Ferroptosis-IN-12 (Cpd-A1) is a ferroptosis inhibitor. Ferroptosis-IN-12 exhibits effective ferroptosis inhibition in Erastin (HY-15763)-treated mouse tubular epithelial cells (mTECs) and improves kidney function, alleviates renal tubular damage, and reduces inflammation in a dose-dependent manner in acute kidney injury (AKI) mouse models induced by ischemia/reperfusion (I/R) or cecal ligation and puncture (CLP). Ferroptosis-IN-12 demonstrates good plasma stability and high distribution in kidney tissues in pharmacokinetic studies in mice. Ferroptosis-IN-12 holds promise for research in the field of acute kidney injury (AKI) .

HY-112338

C188 CPD188	STAT Apoptosis	Cancer
C188 (CPD188) is a STAT3 inhibitor with anticancer effects. C188 inhibits STAT3 SH2/pY-peptide binding (IC₅₀ of 20 µM against pY-peptide binding) and IL-6-mediated STAT3 phosphorylation. C188 is selective for STAT3 over STAT1. C188 inhibits nuclear-to-cytoplasmic translocation of Stat3. C188 shows highly active induces apoptosis in breast cancer cell lines with constitutive Stat3 activation (EC₅₀s of 0.73 µM, 3.96 µM, and 7.01 µM in MDA-MB-468, MDA-MB-231, and MDA-MB-435 cultures, respectively) .

HY-P990114

Anti-Canine PD-L1/B7-H1 Antibody (JC071)	PD-1/PD-L1	Others
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is an anti-canine PD-L1/B7-H1 IgG1 monoclonal antibody. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can specifically bind to CHO-PDL1 cells and K562-cCD20-cPD-L1 cells. Anti-Canine PD-L1/B7-H1 Antibody (JC071) can enhance the level of IFN-γ. Anti-Canine PD-L1/B7-H1 Antibody (JC071) is often used in western blot experiments .

Cat. No.	Product Name	Target	Research Area